HC Wainwright Has Optimistic Opinion of Precigen Q4 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at HC Wainwright boosted their Q4 2026 EPS estimates for shares of Precigen in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.11 per share for the quarter, up from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Precigen’s Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.17 EPS and Q4 2027 earnings at $0.19 EPS.

PGEN has been the subject of a number of other reports. Wall Street Zen downgraded shares of Precigen from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Zacks Research cut Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Raymond James Financial set a $12.00 target price on Precigen in a research report on Thursday. B. Riley Financial initiated coverage on shares of Precigen in a research report on Friday, September 25th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Precigen Trading Down 16.4%

Precigen stock opened at $4.22 on Friday. Precigen has a fifty-two week low of $3.04 and a fifty-two week high of $8.98. The firm’s fifty day moving average price is $7.03 and its 200-day moving average price is $5.28. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The stock has a market cap of $1.50 billion, a P/E ratio of 42.20 and a beta of 1.01.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The company had revenue of $74.15 million during the quarter, compared to analysts’ expectations of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 86.42%. Precigen’s revenue for the quarter was up 2437.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.06) earnings per share.

Insider Activity

In other news, COO Rutul Shah sold 34,658 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $7.50, for a total transaction of $259,935.00. Following the completion of the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at approximately $3,487,590. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the sale, the director owned 17,100 shares of the company’s stock, valued at approximately $127,224. This represents a 91.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 235,000 shares of company stock valued at $1,751,400. Insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Several large investors have recently added to or reduced their stakes in the stock. Patient Capital Management LLC purchased a new position in Precigen during the 2nd quarter valued at $108,511,000. BlackRock Inc. purchased a new position in shares of Precigen during the second quarter valued at about $97,737,000. Bank of America Corp DE bought a new position in Precigen in the second quarter worth about $10,536,000. Wellington Management Group LLP raised its stake in Precigen by 9.2% in the second quarter. Wellington Management Group LLP now owns 555,230 shares of the biotechnology company’s stock worth $3,165,000 after buying an additional 46,796 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Precigen in the second quarter worth about $2,705,000. Institutional investors own 33.51% of the company’s stock.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for every quarter from Q4 2026 through Q4 2027, including its Q4 2027 forecast to $0.19 from $0.14. The firm reiterated its Buy rating and $18 price target, signaling increased confidence in expected earnings. Precigen stock coverage
• Positive Sentiment: Precigen reported PAPZIMEOS revenue of $72.9 million in Q3, up 37% sequentially, and said it generated positive cash flow a quarter ahead of guidance. The company also reported $35.8 million in net income and received FDA Platform Technology Designation for its AdenoVerse platform. Q3 results and business update
• Positive Sentiment: Citizens JMP raised its price target to $12 from $11 and maintained a Market Outperform rating, citing a higher PAPZIMEOS sales outlook after the quarterly update. Citizens JMP price-target coverage
• Neutral Sentiment: Q3 EPS was $0.08. That topped the $0.06 consensus cited by some coverage, but fell short of the $0.09 estimate cited by Zacks, making the earnings comparison mixed. Revenue of $74.15 million exceeded the $71.55 million estimate. Zacks Q3 earnings coverage

About Precigen

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.